RxDoctor Payments Data

Eric True, PA

Medical · Lufkin, TXNPI 1962511899

Payments from drug & device makers

$2,705in general payments, 2019–2025

Across 141 payments — averaging $19.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$702
  • Novo Nordisk$506
  • Boehringer Ingelheim$289
  • Lilly USA, LLC$277
  • Pfizer$158
  • Amgen$133
  • plus $640 from 11 others

What the payments were for

  • Food & beverage$2,66098%
  • Education$452%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,705 in reported general payments places this provider in the 70th percentile of 1,490 medical providers in Texas.

See all medical providers in Texas

Medicare billing

Part B allowed, 2024
$33,523
Medicare patients
120
Services billed
478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide79$157,048
JardianceEmpagliflozin72$71,540
Synjardy XrEmpagliflozin/Metformin Hcl59$56,733
TrulicityDulaglutide21$52,474
Trelegy ElliptaFluticasone/Umeclidin/Vilanter55$41,684
FarxigaDapagliflozin Propanediol40$32,549
MounjaroTirzepatide19$29,824
Xigduo XrDapaglifloz Propaned/Metformin20$29,510
EliquisApixaban18$14,903
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$10,187
JanuviaSitagliptin Phosphate18$9,980
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$9,397
LinzessLinaclotide17$8,884
Rosuvastatin Calcium94$3,022
Atorvastatin Calcium357$2,865

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$506$157,04879 claims
Boehringer IngelheimJardiance, Synjardy Xr$289$128,273131 claims
Lilly USA, LLCTrulicity, Mounjaro$277$82,29740 claims
AstraZenecaFarxiga, Breztri Aerosphere$702$42,73754 claims
GSKTrelegy Ellipta$132$41,68455 claims
PfizerEliquis$158$14,90318 claims
AbbVieLinzess$76$8,88417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,490 medical providers in Texas.

Other medical in Lufkin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →